Solo educación · requiere revisión profesional
Cagrilintide · Amylin analogue in trials
A long-acting amylin analogue studied alone and combined with semaglutide (CagriSema).
Revisado médicamente por Bernard Garcia, MD
Qué es
Cagrilintide is an investigational long-acting analogue of amylin, a hormone released with insulin that affects satiety and gastric emptying. It is studied on its own and, more prominently, in a fixed combination with semaglutide known as CagriSema, which is in phase 3 trials.
Cómo funciona
Amylin analogues act on appetite centres through a different receptor from GLP-1, which is the rationale for combining the two. Phase 2 and 3 data report average weight reduction over 68 weeks; approval decisions are pending.
Estado de la investigación
| Área de investigación | Estado |
|---|---|
| Weight management (with semaglutide) | Phase 3 trials · not approved |
| Weight management (alone) | Phase 2 · not approved |
| Long-term safety | Not established |
| Regulatory status (US FDA) | Investigational · no approval |
El estado refleja únicamente el contexto de la investigación publicada y no constituye una afirmación de seguridad, eficacia o idoneidad para ninguna persona.
¿Es legal?
Cagrilintide is investigational and not approved in any country. This is a general note, not legal advice.
Preguntas frecuentes
Is cagrilintide available?
No. It is in clinical trials only.
How does it differ from GLP-1 medicines?
It mimics amylin, a different hormone, and is studied mainly as an add-on to semaglutide.
Will this page change?
Yes — it is re-reviewed when trial results or regulatory decisions are published.
Siguiente paso
Siguiente paso: una consulta confidencial de 3 minutos, revisada por un profesional con licencia. No se promete ni se da a entender ningún tratamiento.
Gratis · unos 10 minutos · revisado por un médico con licencia
Educación general · No es consejo médico · Se requiere aprobación profesional